(Q38484327)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12705998%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12705998%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

main subject

prostatic hypertrophy

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12705998%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

J A Erkens

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12705998%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

J J M C H de la Rosette

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12705998%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

H G M Leufkens

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12705998%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

R M C Herings

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12705998%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

language of work or name

English

0 references

publication date

1 May 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12705998%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12705998%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12705998%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12705998%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

528-534

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12705998%20AND%20SRC:MED&resulttype=core&format=json

The development of human benign prostatic hyperplasia with age

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

Clinical uroselectivity: a 3-year follow-up in general practice. BPH Group in General Practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

A chronic disease score from automated pharmacy data

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

Therapeutic controversies: clinical treatment of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

How do symptoms indicative of BPH progress in real life practice? The UK experience

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

Natural history of prostatism: risk factors for acute urinary retention

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

The progression of benign prostatic hyperplasia: examining the evidence and determining the risk

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

Variability of Clinical and Pressure-Flow Study Variables After 6 Months of Watchful Waiting in Patients with Lower Urinary Tract Symptoms and Benign Prostatic Enlargement

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

The urologist view of BPH progression: results of an international survey

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

Natural history of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

Long-term effects on BPH of medical and instrumental therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900089-7

7 January 2021

10.1016/S0302-2838(03)00089-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12705998%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference